Raymond James Financial
PRME icon

Raymond James Financial’s Prime Medicine PRME Stock Holding History

Raymond James Financial’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.9K Sell
12,044
-15,000
-55% -$57.1K ﹤0.01% 5139
2025
Q4 		$93.8K Sell
27,044
-4,763
-15% -$21.2K ﹤0.01% 4938
2025
Q3 		$176K Buy
31,807
+30,243
+1,934% +$123K ﹤0.01% 4658
2025
Q2 		$3.86K Buy
+1,564
New +$2.41K ﹤0.01% 6246

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Raymond James Financial's PRME Position: Q1 2026 in Review

Raymond James Financial reduced its Prime Medicine (PRME) stake by 55% in Q1 2026, selling an estimated $57.1K and leaving 12,044 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5139.

Raymond James Financial first reported a position in PRME in Q2 2025 and has held it in 4 quarters since. The position peaked at $176K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Raymond James Financial held 12,044 shares of Prime Medicine worth $41.9K as of Q1 2026.
  • Raymond James Financial sold 15,000 Prime Medicine shares in Q1 2026, an estimated $57.1K.
  • Prime Medicine made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5139 holding.
  • Raymond James Financial first reported a position in Prime Medicine in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Prime Medicine position peaked at $176K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.